In a landmark deal announced Thursday, President Donald Trump negotiated dramatically lower costs for weight-loss drugs produced by pharmaceutical giants Eli Lilly and Novo Nordisk, which could benefit Medicare and Medicaid patients, as well as Americans paying out of pocket. But here’s the skinny: What the president negotiated should not be reserved for big companies that play his game.
- 1Dan DiamondandJM RiegerA closer look at Trump’s apparent struggles to fight off sleep in the Oval Office
- 2ColumnCarolyn HaxCarolyn Hax: Husband goes rogue, asks wealthy father-in-law for money
- 3OpinionEditorial BoardZohran Mamdani drops the mask
- 4Aaron GreggandShannon NajmabadiA critical part of the economy isn’t hiring. Bosses explain why.
- 5Akilah JohnsonHow a childhood virus can contribute to dementia later and what you can do
